Skip to main content

Table 1 Significant correlations of GMD expression with drug response in the pancancer dataset and in individual cancer categories satisfying |ρ| > 0.4 and pFDR < 0.05

From: Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines

Cancer category GMD Agent ρ pFDR Sample size
Pancancer KDM2B XMD13-2 − 0.4319 3.99 × 10–24 590
Pancancer KDM2B BMS-345541 − 0.4313 3.99 × 10–24 590
Pancancer KDM2B T0901317 − 0.4231 3.83 × 10–23 586
Pancancer DNMT1 Zibotentan − 0.4214 3.83 × 10–23 591
Pancancer KDM2B NPK76-II-72–1 − 0.4174 1.01 × 10–22 591
Pancancer APOBEC3G Z-LLNle-CHO − 0.4148 2.64 × 10–9 225
Pancancer KDM2B Zibotentan − 0.4139 2.37 × 10–22 591
Pancancer KDM2B Quizartinib − 0.4095 8.98 × 10–22 589
Pancancer KDM2B UNC1215 − 0.4062 5.08 × 10–21 574
Pancancer KDM2B Daporinad − 0.4057 7.77 × 10–21 569
Pancancer KDM2B Vorinostat − 0.4057 2.13 × 10–19 527
Pancancer DNMT1 XMD13-2 − 0.4043 2.87 × 10–21 590
Pancancer EHMT2 NPK76-II-72–1 − 0.4041 2.87 × 10–21 591
Pancancer DNMT1 Daporinad − 0.4036 1.21 × 10–20 569
Pancancer KDM2B XMD14-99 − 0.4035 3.24 × 10–21 590
Pancancer KDM2B BX-912 − 0.4031 3.37 × 10–21 590
Pancancer KDM2B I-BET-762 − 0.4020 5.08 × 10–21 587
Pancancer KDM2B Tubastatin A − 0.4011 5.97 × 10–21 587
BREAST GADD45A Refametinib − 0.8026 0.0002 40
MATBCL BMI1 5-Fluorouracil − 0.7900 0.0440 27
SCLC APOBEC3A GSK1070916 0.7764 0.0399 29
BREAST APOBEC3C Cetuximab − 0.7278 0.0242 38
BREAST APOBEC3G Cetuximab − 0.7105 0.0399 38
BREAST GADD45A Trametinib − 0.7012 0.0399 39
NSCLC IDH1 (5Z)-7-Oxozeaenol 0.5171 0.0242 91
  1. All agents listed in table were from the GDSC dataset. Abbreviations for cancer categories are provided in Table S2 and in the list of abbreviations. ρ, Spearman correlation coefficient; pFDR, FDR adjusted p-value; Sample size, the number of available cell lines in each category with available RNA-seq expression data and drug response data